BRAF and melanoma: To confirm the role of this transcription factor in the induction of a tolerant phenotype, they co-treated melanoma PDXs with a combination of BRAF/MEK inhibitors and an RXR antagonist, which resulted in a decrease in the levels of NSCLC markers and a delay in the acquisition of resistance [51].